Global Ustekinumab Market Research Report 2022

Ustekinumab is a human immunoglobulin (Ig) G1 kappa monoclonal antibody directed against interleukin(IL)-12 and IL-23, which are cytokines that are involved in immune and inflammatory responses.
Due to the COVID-19 pandemic, the global Ustekinumab market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the forecast period 2022-2028. Fully considering the economic change by this health crisis, the Europe Ustekinumab market is estimated at US$ million in 2022, while the United States and China are forecast to reach US$ million and US$ million by 2028, respectively. The proportion of the United States is % in 2022, while Chinese percentage is %, and it is predicted that China market share will reach % in 2028, trailing a CAGR of % through the analysis period. As for the Europe Ustekinumab landscape, Germany is projected to reach US$ million by 2028. and in Asia, the notable markets are Japan and South Korea, CAGR is % and % respectively for the next 6-year period.
Intravenous accounting for % of the Ustekinumab global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While Arthritis segment is altered to an % CAGR throughout this forecast period and will hold a share about % in 2028.
The global major manufacturers of Ustekinumab include Meiji, Johnson & Johnson, Alvotech, Fuji Pharma, Mitsubishi Tanabe, Stada, EPIRUS BioPharma, Formycon and NeuClone, etc. In terms of revenue, the global 3 largest players have a % market share of Ustekinumab in 2021.
This report focuses on Ustekinumab volume and value at the global level, regional level, and company level. From a global perspective, this report represents overall Ustekinumab market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan, etc.
Global Ustekinumab Market: Segment Analysis
The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2017 to 2028. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
Segment by Type
Intravenous
Subcutaneous
Segment by Application
Arthritis
Colitis
Lupus Erythematosus
Myositis Multiplex With Palmoplantar Pustulosis
Cirrhosis Of The Liver
Sarcoidosis
Diabetes
Other
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
By Company
Meiji
Johnson & Johnson
Alvotech
Fuji Pharma
Mitsubishi Tanabe
Stada
EPIRUS BioPharma
Formycon
NeuClone
Outlook Therapeutics
Harvest Moon Pharma
BioXpress